AESOPS: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of opportunistic screening and stepped care interventions for older hazardous alcohol users in primary care

JM Watson,1 H Crosby,2 VM Dale,1 G Tober,2 Q Wu,1 J Lang,2 R McGovern,3 D Newbury-Birch,3 S Parrott,1 JM Bland,1 C Drummond,4 C Godfrey,1 E Kaner3 and S Coulton5* on behalf of the AESOPS trial team

1Department of Health Sciences, University of York, York, UK
2Leeds Addiction Unit, Leeds, UK
3Institute of Health and Society, Newcastle University, Newcastle, UK
4National Addiction Centre, Institute of Psychiatry, King’s College London, London, UK
5Centre for Health Service Studies, University of Kent, Canterbury, UK

*Corresponding author

Scientific summary

Alcohol: Evaluating Stepped care in Older Populations Study (AESOPS)

Health Technology Assessment 2013; Vol. 17: No. 25
DOI: 10.3310/hta17250

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

There is clear evidence of the detrimental impact of hazardous alcohol consumption on the physical and mental health of the population. Estimates suggest that hazardous alcohol consumption annually accounts for 150,000 hospital admissions and between 15,000 and 22,000 deaths in the UK. In the older population, hazardous alcohol consumption is associated with a wide range of physical, psychological and social problems. There is evidence of an association between increased alcohol consumption and increased risk of coronary heart disease, hypertension, haemorrhagic and ischaemic stroke, increased rates of alcohol-related liver disease and increased risk of a range of cancers. Alcohol has been identified as one of the three main risk factors for falls. Excessive alcohol consumption in older age can also contribute to the onset of dementia and other age-related cognitive deficits and is implicated in one-third of all suicides in the older population.

Objectives

To compare the clinical effectiveness and cost-effectiveness of a stepped care intervention against a minimal intervention in the treatment of older hazardous alcohol users in primary care.

Design

A multicentre, pragmatic, two-armed randomised controlled trial with an economic evaluation. Randomisation was performed by a remote service. Treating nurses, therapists and participants were aware of allocation result, and outcome assessment was average drinks per day (ADD) derived from the extended Alcohol Use Disorders Identification Test – Consumption (3-item) (AUDIT-C).

Setting

General practices in primary care in England and Scotland.

Participants

Participants were eligible to participate in the study if they were aged ≥55 years and scored ≥8 on the Alcohol Use Disorders Identification Test (AUDIT). Following screening, a total of 529 participants were randomised in the study.

Interventions

Participants in the minimal intervention group received a 5-minute brief advice intervention with the practice nurse or research nurse involving feedback of the results of the screening and discussion regarding the health consequences of continued hazardous alcohol consumption. Those in the stepped care arm initially received a 20-minute session of behavioural change counselling (step 1), with referral to step 2 (motivational enhancement therapy) and step 3 (local specialist alcohol services) if indicated. Sessions were recorded to ensure treatment fidelity.
Main outcome measures

The primary outcome was ADD derived from the extended AUDIT-C at 12 months. Secondary outcomes were alcohol-related problems assessed using the Drinking Problems Index (DPI) at 6 and 12 months; ADD (derived from the extended AUDIT-C) at 6 months; extended AUDIT-C score at 6 and 12 months; health-related quality of life (HRQoL) at 6 and 12 months; quality-adjusted life-years (QALYs) (for cost–utility analysis derived from European Quality of Life-5 Dimensions); and health and social care resource use associated with the two groups.

Results

Both groups reduced alcohol consumption between baseline and 12 months. There were no significant differences in ADD between the treatment groups at 12 months. Stepped care had a marginally higher ADD [1.129; standard deviation (SD) 0.037] than minimal intervention (1.104; SD 0.037), but not significantly so. At months 6 and 12, the stepped care group had a lower DPI score than the minimal intervention group, but the difference was not statistically significant at the 5% level. At month 6, the stepped care group had a lower ADD than the minimal intervention group, but this difference was not statistically significant. The stepped care group had a lower mental component score [measured using the Short Form Questionnaire-12 items (SF-12)] than the minimal intervention group at month 6 and month 12. The stepped care group also had a lower physical component score at month 6 and month 12. These differences were not significant at the 5% level.

The cost-effectiveness results indicated that the overall average cost per patient, taking into account health and social care resource use, was £488 (SD £826) in the stepped care group and £482 (SD £826) in the minimal intervention group at month 6. The mean QALY gains were slightly greater in the stepped care group than in the minimal intervention group, with a mean difference of 0.0058 [95% confidence interval (CI) –0.0018 to 0.0133], generating an incremental cost-effectiveness ratio (ICER) of £1100 per QALY gained. At month 12, participants in the stepped care group incurred fewer costs, with a mean difference of –£194 (95% CI –£585 to £198), and had gained 0.0117 more QALYs (95% CI –0.0084 to 0.0318) than the control group. From an economic perspective the minimal intervention, therefore, was dominated by stepped care. Given thresholds of £20,000–30,000 per additional QALY gained, the probability that stepped care is more cost-effective is 81–86% at the 6-month follow-up and 93.5–93.8% at 12 months.

A sensitivity analysis that excluded extreme cases altered the average costs of interventions; the ICERs were £8496 per QALY at 6 months and £4224 per QALY at 12 months. The probability that stepped care is more cost-effective ranges between 80% and 88% at 6 months, and between 87% and 90% at 12 months, using the £20,000–30,000 per QALY gained threshold.

The prevalence of hazardous alcohol consumption in those aged ≥55 years had been estimated at 15% in the general population. Screening results from this study found this to be only 7.5%. Fidelity process rating identified significant differences between the minimal and step 1 interventions, indicating that the two types of intervention were distinct. There were no significant differences in the rating scores between practice or research nurses with different levels of experience (specialist vs non-specialist practitioners).

Conclusions

Stepped care does not confer an advantage over minimal intervention in terms of reduction in alcohol consumption at 12 months post intervention when compared with a 5-minute brief (minimal) intervention. Our cost-effectiveness analysis examining QALY gains suggested that the stepped care intervention is more likely to generate greater health benefits and achieves better value for money compared with minimal
intervention, but caution is required given the uncertainty surrounding the estimates and the absence of a statistically significant difference in effectiveness outcomes.

**Implications for health care**
There is no evidence that a stepped care approach reduces alcohol consumption in terms of ADD among older hazardous alcohol users after 12 months, or improves AUDIT score, alcohol-related problems or quality of life after 6 or 12 months.

**Recommendations for future research**
The experience of conducting this study alongside the results obtained has prompted a number of suggestions for future research:

- What factors facilitate or hinder the conduct of research in primary care settings?
- What is the clinical effectiveness and cost-effectiveness of community-based screening and self-directed ultra-brief interventions for hazardous alcohol users compared with screening alone?
- What is the clinical effectiveness and cost-effectiveness of motivational enhancement therapy for opportunistically identified, non-treatment-seeking harmful alcohol users delivered in primary care?
- What are the longer-term clinical and economic impacts of stepped care interventions?

**Study registration**
This trial is registered as ISRCTN52557360.

**Funding**
This project was funded by the NIHR Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 17, No. 25. See the HTA programme website for further project information.

**Publication**
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)

Five-year impact factor: 5.596

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is assessed for inclusion in the Database of Abstracts of Reviews of Effects.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 06/304/142. The contractual start date was in April 2007. The draft report began editorial review in April 2012 and was accepted for publication in October 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2013. This work was produced by Watson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Health Sciences, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Tom Marshall  Reader in Primary Care, School of Health and Population Sciences, University of Birmingham, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Honorary Professor, Business School, Winchester University and Medical School, University of Warwick, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, NICE, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professorial Research Associate, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk